 Shares of Equillium Inc. tumbled 12.6 in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 trial its itolizumab for the treatment of hospitalized COVID-19 patients at this time. The company said its decision was based on a review of recent updates regarding the efficacy of COVID-19 vaccine candidates and other treatment options. 